Evidence map›Paper›PMID 42123689›Full record

ReviewInternational journal of molecular sciences2026

The Complosome: An Emerging Intracellular Complement Network in Cancer Development and Therapy.

Łukasz Zadroga, Filip Lewandowski, Dominika Bębnowska, Adam Majchrzak, Alina Czyż, Paulina Niedźwiedzka-Rystwej

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Łukasz ZadrogaDepartment of General, Dental and Interventional Radiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.ORCID 0009-0002-8632-4059
Filip LewandowskiInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0009-0002-5986-5845
Dominika BębnowskaInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0003-3689-2381
Adam MajchrzakDepartment of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland.
Alina CzyżCenter for Experimental Immunology and Immunobiology in Infectious Diseases and Cancer, University of Szczecin, 71-412 Szczecin, Poland.
Paulina Niedźwiedzka-RystwejInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0003-4065-3842

Funding

Ministry of Science and Higher Education RID/SP/0045/2024/01
6 · The paper itself

Abstract

The complement system is traditionally recognized as a major effector of innate immunity, essential for pathogen clearance, inflammation and the maintenance of tissue homeostasis. In recent years, however, its role in cancer has been substantially redefined. Beyond its canonical extracellular activity, complement has emerged as a multifaceted regulator of tumor biology, acting not only within the tumor microenvironment but also intracellularly through the recently described intracellular complement system (complosome). While extracellular complement primarily shapes immune responses and the tumor microenvironment, the complosome directly regulates fundamental cellular processes, including metabolism, proliferation, autophagy, stress responses and cell survival. In this review, we discuss current evidence on the canonical and non-canonical roles of complement in cancer. Importantly, complement signaling exhibits a strong context-dependent duality, exerting either tumor-promoting or tumor-restraining effects depending on the tumor type, disease stage, cellular source, and localization. Taken together, the available evidence indicates that the complosome is not merely an extension of classical complement biology, but a distinct and biologically significant signaling network that rewrites our understanding of complement in cancer. Its growing relevance in tumor development and therapy resistance positions it as a promising target for future mechanistic studies and innovative therapeutic interventions.

Indexed as

Complement System ProteinsNeoplasmsAnimalsComplement ActivationHumansImmunity, InnateSignal TransductionTumor MicroenvironmentComplement System Proteinscancercomplementcomplosomeimmune evasiontumor development

Identifiers

PMID42123689
PMCPMC13163260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.